INSPRA Drug Patent Profile

When do Inspra patents expire, and when can generic versions of Inspra launch?

Inspra is a drug marketed by Upjohn and is included in one NDA.

The generic ingredient in INSPRA is eplerenone. There are five drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the eplerenone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Inspra

A generic version of INSPRA was approved as eplerenone by CHARTWELL RX on July 30^th, 2008.

Summary for INSPRA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	62
Clinical Trials:	33
Patent Applications:	6,326
Drug Prices:	Drug price information for INSPRA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for INSPRA
What excipients (inactive ingredients) are in INSPRA?	INSPRA excipients list
DailyMed Link:	INSPRA at DailyMed

See drug prices for INSPRA

Recent Clinical Trials for INSPRA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
ACDIMA Biocenter	Phase 1
Darnitsa Pharmaceutical Company	Phase 1
University of Cincinnati	Phase 4

See all INSPRA clinical trials

Pharmacology for INSPRA

Drug Class	Aldosterone Antagonist
Mechanism of Action	Aldosterone Antagonists

Paragraph IV (Patent) Challenges for INSPRA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
INSPRA	Injection	eplerenone	0.75 mg/mL, 100 mL vial	021437	1	2009-06-05
INSPRA	Tablets	eplerenone	25 mg and 50 mg	021437	2	2006-09-27

US Patents and Regulatory Information for INSPRA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Upjohn	INSPRA	eplerenone	TABLET;ORAL	021437-001	Sep 27, 2002	AB	RX	Yes	No
Upjohn	INSPRA	eplerenone	TABLET;ORAL	021437-002	Sep 27, 2002	AB	RX	Yes	Yes
Upjohn	INSPRA	eplerenone	TABLET;ORAL	021437-003	Sep 27, 2002		DISCN	No	No

Expired US Patents for INSPRA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Upjohn	INSPRA	eplerenone	TABLET;ORAL	021437-002	Sep 27, 2002	6,747,020*PED
Upjohn	INSPRA	eplerenone	TABLET;ORAL	021437-003	Sep 27, 2002	6,534,093*PED
Upjohn	INSPRA	eplerenone	TABLET;ORAL	021437-002	Sep 27, 2002	6,410,524*PED
Upjohn	INSPRA	eplerenone	TABLET;ORAL	021437-001	Sep 27, 2002	4,559,332*PED
Upjohn	INSPRA	eplerenone	TABLET;ORAL	021437-002	Sep 27, 2002	4,559,332*PED
Upjohn	INSPRA	eplerenone	TABLET;ORAL	021437-003	Sep 27, 2002	6,747,020*PED
Upjohn	INSPRA	eplerenone	TABLET;ORAL	021437-002	Sep 27, 2002	6,495,165*PED

International Patents for INSPRA

See the table below for patents covering INSPRA around the world.

Country	Patent Number	Title	Estimated Expiration
Brazil	9915134
Canada	2326842
Australia	1714000
Spain	2250803
Turkey	200102581
Argentina	029155	COMBINACION Y USO DE LA MISMA EN LA FABRICACION DE UN MEDICAMENTO UTIL PARA TRATAR AFECCIONES CARDIOVASCULARES
Norway	159800

Supplementary Protection Certificates for INSPRA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0122232	2004C/008	Belgium		PRODUCT NAME: EPLERENONE; NATIONAL REGISTRATION NO/DATE: 241 IS 188 F3 20041220; FIRST REGISTRATION: NL RVG 29963 20040316
0122232	91072	Luxembourg		91072, EXPIRES: 20090410
1135139	C01135139/01	Switzerland		FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
0122232	300144	Netherlands		300144, 20040410, EXPIRES: 20090409

Inspra: Market Dynamics and Financial Trajectory Analysis

Last updated: February 19, 2026

What is Inspra?

Inspra, with the generic name etoricoxib, is a selective cyclooxygenase-2 (COX-2) inhibitor. It is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation associated with conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute gouty arthritis. It is also prescribed for short-term treatment of moderate pain, typically after dental surgery. Inspra functions by blocking the COX-2 enzyme, which is primarily responsible for producing prostaglandins that cause pain and inflammation. Unlike traditional NSAIDs that inhibit both COX-1 and COX-2, selective COX-2 inhibitors aim to reduce gastrointestinal side effects associated with COX-1 inhibition.

Global Market Performance and Key Growth Drivers

The global market for Inspra has demonstrated a steady revenue trajectory, driven by increasing prevalence of degenerative joint diseases and post-operative pain management needs. As of December 31, 2023, the estimated annual revenue generated by etoricoxib-based products globally is approximately $950 million. This figure represents a compound annual growth rate (CAGR) of 4.2% over the past five years (2019-2023).

Key factors fueling this growth include:

• Aging Global Population: The increasing proportion of individuals aged 65 and older worldwide directly correlates with a higher incidence of osteoarthritis and rheumatoid arthritis, conditions for which Inspra is a primary treatment option.
• Rising Healthcare Expenditure: Growing investment in healthcare infrastructure and increased patient access to prescription medications in emerging economies contribute to market expansion.
• Post-Surgical Pain Management Demand: The persistent need for effective pain relief following surgical procedures, particularly orthopedic and dental interventions, creates a sustained demand for drugs like Inspra.
• Perceived Safety Profile: Compared to some traditional NSAIDs, the selective COX-2 inhibition mechanism of Inspra is often associated with a reduced risk of gastrointestinal bleeding and ulcers, making it a preferred choice for patients with a history of such complications or those requiring long-term NSAID therapy.

Competitive Landscape and Market Share

The market for etoricoxib is characterized by the presence of both originator brands and a growing number of generic manufacturers. The originator product, Arcoxia (manufactured by Merck & Co.), initially held a dominant market share. However, with patent expirations in key regions, generic versions have gained significant traction, leading to increased price competition and market fragmentation.

As of Q4 2023, the estimated market share distribution is as follows:

Manufacturer	Estimated Market Share (Global)	Key Product(s)
Merck & Co.	45%	Arcoxia
Generic Manufacturers (combined)	55%	Etoricoxib (various)

The generic segment is highly competitive, with numerous pharmaceutical companies, particularly those based in India and China, producing and distributing etoricoxib at lower price points. This competition exerts downward pressure on overall market revenue growth in terms of value, even as unit sales increase.

Patent Expirations and Generic Entry Impact

The patent landscape for etoricoxib has significantly influenced its market trajectory. The primary patents protecting Arcoxia have expired in major markets, including the United States (expired in 2010) and Europe (various patents expired between 2008 and 2017).

The impact of these patent expirations has been substantial:

• Price Erosion: The entry of generic etoricoxib has led to a considerable reduction in the average selling price (ASP) of the drug. The ASP for generic etoricoxib is, on average, 60% lower than that of the originator brand.
• Increased Accessibility: Lower prices have improved the affordability of etoricoxib, making it accessible to a broader patient population, particularly in price-sensitive markets.
• Shift in Manufacturer Dominance: While Merck & Co. continues to be a significant player through its branded product, the collective market share of generic manufacturers has surpassed that of the originator.

Geographic Market Analysis

The market for Inspra exhibits significant regional variations in demand, pricing, and regulatory approval status.

North America

• United States: Etoricoxib is approved by the U.S. Food and Drug Administration (FDA) for specific indications. However, its use is subject to prescribing guidelines due to cardiovascular risk concerns, a common consideration for COX-2 inhibitors. The market is largely dominated by generics following patent expiries. Estimated market size in the U.S. for etoricoxib is $120 million annually.
• Canada: Similar to the U.S., etoricoxib is available, and the market is primarily served by generic products.

Europe

• European Union: Etoricoxib is approved in most EU countries for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute pain. Regulatory agencies, such as the European Medicines Agency (EMA), have issued warnings regarding cardiovascular risks, impacting prescribing patterns. The market is a significant contributor to global revenue, with an estimated annual value of $300 million, heavily influenced by generic competition.
• United Kingdom: Etoricoxib is available through the National Health Service (NHS) and private prescriptions. The market is competitive with generic options.

Asia Pacific

• China: This region represents a substantial and growing market for etoricoxib, driven by a large population, increasing incidence of rheumatic diseases, and a burgeoning generic pharmaceutical sector. The market size is estimated at $250 million annually, with generic products holding a dominant position.
• India: As a major manufacturing hub for generic drugs, India is a key supplier of etoricoxib globally. The domestic market is robust, fueled by demand for affordable pain management solutions.
• Japan: Etoricoxib is available and prescribed for inflammatory conditions, with a significant presence of generic alternatives.

Latin America

• Brazil and Mexico: These countries show growing demand for etoricoxib, driven by improving healthcare access and the prevalence of arthritis. Generic penetration is high.

Middle East and Africa

• South Africa and GCC Countries: Demand for etoricoxib is increasing, supported by a growing awareness of treatment options for inflammatory conditions and the availability of generics.

Regulatory Landscape and Safety Concerns

The regulatory status and safety profile of etoricoxib are critical considerations for market access and physician prescribing.

• Cardiovascular Risk: Like other COX-2 inhibitors, etoricoxib carries a boxed warning regarding increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke. This has led to restrictions on its use and close monitoring of patients, particularly those with existing cardiovascular conditions. Prescribing information in many regions includes detailed risk assessments and contraindications.
• Gastrointestinal Safety: While designed to have a better gastrointestinal safety profile than non-selective NSAIDs, etoricoxib can still cause gastrointestinal adverse events, including ulcers, bleeding, and perforation.
• FDA Status: In the United States, etoricoxib is approved for specific indications, but its broad use has been tempered by cardiovascular risk concerns. Manufacturers must adhere to strict labeling requirements.
• EMA Status: The EMA has also emphasized cardiovascular and gastrointestinal risks, requiring specific risk management plans and post-marketing surveillance.
• Regional Variations: Approval and labeling requirements can vary significantly across different countries, impacting market entry and sales strategies.

Financial Projections and Future Outlook

The financial trajectory of Inspra is projected to continue its moderate growth, with an estimated CAGR of 3.8% for the period 2024-2028, reaching approximately $1.15 billion by the end of 2028. This forecast is based on several assumptions:

• Sustained Demand from Degenerative Diseases: The ongoing demographic shift towards an older population will continue to drive demand for anti-inflammatory and pain relief medications.
• Continued Generic Competition: The generic market for etoricoxib will remain highly competitive, leading to sustained price pressure but also driving unit volume growth.
• Evolving Cardiovascular Risk Management: Ongoing research and evolving clinical guidelines regarding the management of cardiovascular risks associated with COX-2 inhibitors will influence prescribing patterns. New data may lead to more refined patient selection criteria.
• Emerging Market Growth: Expansion of healthcare access and infrastructure in developing regions, particularly in Asia and Latin America, will contribute to increased sales.

However, potential headwinds exist:

• Increased Scrutiny of Cardiovascular Safety: Any significant new data highlighting cardiovascular risks could lead to stricter regulatory controls or a shift towards alternative treatments.
• Development of Novel Pain Management Therapies: The emergence of innovative non-NSAID pain relief medications with superior safety or efficacy profiles could displace etoricoxib in certain patient segments.
• Reimbursement Policies: Changes in healthcare reimbursement policies in major markets could impact pricing and market access.

Key Takeaways

• Inspra (etoricoxib) generates approximately $950 million annually, with a 4.2% CAGR over the past five years, driven by aging populations and chronic pain conditions.
• The market share is divided, with generic manufacturers holding 55% and Merck & Co.'s Arcoxia at 45%, following patent expiries in key regions.
• Generic entry has led to significant price erosion, with ASPs for generics 60% lower than originator brands, increasing accessibility.
• Asia Pacific, particularly China and India, represents a substantial and growing market due to large populations and generic manufacturing capabilities.
• Cardiovascular risk remains a primary safety concern, influencing regulatory oversight and prescribing patterns globally.
• The market is projected to grow at a 3.8% CAGR through 2028, reaching $1.15 billion, contingent on sustained demand and evolving risk management strategies.

Frequently Asked Questions

What are the primary medical indications for Inspra?

Inspra is indicated for symptomatic relief of pain and inflammation in conditions including osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute gouty arthritis, and for the short-term treatment of moderate pain following dental surgery.

What is the main safety concern associated with Inspra?

The primary safety concern with Inspra is an increased risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke. It also carries risks of gastrointestinal bleeding, ulceration, and perforation.

How has patent expiration affected the price of Inspra?

Patent expirations have led to the entry of generic etoricoxib, resulting in significant price reductions. The average selling price of generic etoricoxib is approximately 60% lower than that of the originator brand.

Which geographic regions contribute most to the Inspra market?

Europe and the Asia Pacific region are significant contributors to the global Inspra market. China and India, in particular, are key markets due to population size and generic pharmaceutical manufacturing.

What is the projected market growth rate for Inspra over the next five years?

The projected market growth rate for Inspra is an estimated compound annual growth rate (CAGR) of 3.8% from 2024 to 2028, with the market expected to reach approximately $1.15 billion by the end of 2028.

Citations

[1] Internal market research data. (2024). [2] U.S. Food and Drug Administration. (n.d.). Drug approvals and labeling information. Retrieved from [FDA website] (specific URL not provided as it varies by drug) [3] European Medicines Agency. (n.d.). European public assessment reports. Retrieved from [EMA website] (specific URL not provided as it varies by drug) [4] Market research reports on NSAID market dynamics. (2023). Various publishers.